Key Points
Analysts expect $0.925 EPS and $10.99B revenue on May 6.
Novo Nordisk beat EPS in three of last four quarters but missed revenue in three.
Meyka AI rates NONOF B+ based on strong margins and fundamentals.
GLP-1 product momentum and geographic performance are key watch items.
Novo Nordisk A/S (NONOF) reports earnings on May 6, 2026, with analysts expecting $0.925 EPS and $10.99 billion in revenue. The Danish pharmaceutical giant trades at $44.35 with a $197.6 billion market cap. Investors will focus on diabetes and obesity care performance, particularly GLP-1 product momentum. Recent quarters show mixed results, with the company beating EPS estimates but missing revenue targets. Meyka AI rates NONOF with a B+ grade, reflecting solid fundamentals and sector strength. Understanding these expectations helps investors prepare for potential market moves.
Earnings Estimates and Historical Performance
Analysts project $0.925 EPS and $10.99 billion revenue for this earnings report. Looking at the last four quarters, Novo Nordisk shows a mixed track record. In February 2026, the company beat EPS estimates ($0.946 actual vs. $0.922 expected) but missed revenue ($12.39B actual vs. $11.86B estimated). August 2025 saw another EPS beat ($0.94 actual vs. $0.935 expected) with revenue slightly below expectations ($12.13B vs. $12.30B). May 2025 delivered a strong EPS beat ($0.961 vs. $0.885 expected) but revenue fell short ($11.49B vs. $11.96B estimated).
EPS Trend Analysis
Earnings per share have remained relatively stable, ranging from $0.94 to $0.961 over recent quarters. The current estimate of $0.925 represents a slight dip from recent performance. This suggests analysts may be taking a cautious stance heading into this report. The company’s ability to consistently beat EPS estimates indicates strong cost management and operational efficiency.
Revenue Expectations
Revenue estimates have been volatile. The current $10.99 billion estimate is notably lower than recent quarters, which averaged around $12 billion. This decline could reflect seasonal patterns, market conditions, or analyst conservatism. Investors should watch whether the company can maintain pricing power in competitive diabetes and obesity markets.
Key Metrics and What to Watch
Novo Nordisk trades at a P/E ratio of 12.32, below the healthcare sector average, suggesting reasonable valuation. The company carries a 4.14% dividend yield, attractive for income-focused investors. Free cash flow per share stands at $12.65, supporting dividend sustainability and R&D investments.
Diabetes and Obesity Care Segment
This segment drives revenue growth through insulin products, GLP-1 medications, and obesity treatments. GLP-1 drugs like semaglutide continue gaining market share globally. Investors should monitor prescription volumes, pricing trends, and competitive pressures from other manufacturers. The segment’s performance directly impacts overall profitability and stock momentum.
Biopharmaceuticals Division
The biopharm segment focuses on haemophilia treatments, growth disorders, and hormone replacement therapy. This division provides diversification but represents a smaller revenue contributor. Watch for any pipeline updates or regulatory approvals that could accelerate future growth in this area.
Cash Flow and Capital Allocation
Operating cash flow per share reached $26.80, demonstrating strong cash generation. The company maintains a 0.71 debt-to-equity ratio, indicating moderate leverage. Capital expenditure represents 20.4% of revenue, supporting manufacturing capacity and innovation.
Beat or Miss Prediction
Based on historical patterns, Novo Nordisk has beaten EPS estimates in three of the last four quarters. However, revenue misses have been more common, occurring in three of four recent reports. This suggests the company excels at cost control but faces revenue headwinds.
EPS Outlook
The current $0.925 estimate appears achievable given recent performance. The company’s consistent EPS beats suggest management confidence and operational discipline. A beat would reinforce investor confidence in profitability despite market challenges. Missing this estimate would signal unexpected cost pressures or operational issues.
Revenue Forecast
The $10.99 billion revenue estimate represents a significant decline from recent quarters. This conservative estimate may actually favor a beat if market conditions remain stable. However, if GLP-1 demand softens or competitive pressures intensify, the company could miss. Watch for geographic performance, particularly in North America and Europe, which drive substantial revenue.
Meyka AI Grade and Investment Perspective
Meyka AI rates NONOF with a B+ grade, reflecting solid fundamentals and market positioning. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests NONOF offers balanced risk-reward for investors seeking healthcare exposure.
Financial Health Indicators
The company demonstrates strong profitability with a 33.1% net profit margin, among the highest in pharmaceuticals. Return on equity of 61.1% shows efficient capital deployment. Gross margins of 81% provide pricing power and operational flexibility. These metrics support the B+ rating and suggest resilience through market cycles.
Growth Trajectory
Revenue growth of 6.4% year-over-year indicates steady expansion despite competitive pressures. EPS growth of 1.7% reflects margin stability. The company’s ability to grow earnings while managing costs positions it well for long-term value creation. Dividend growth of 17.6% demonstrates commitment to shareholder returns.
Risk Factors
Investors should monitor patent expiration risks, particularly for key GLP-1 products. Regulatory changes in pricing and reimbursement could impact margins. Competitive threats from biosimilar manufacturers and new entrants require ongoing attention. Currency fluctuations affect international revenue translation.
Final Thoughts
Novo Nordisk’s May 6 earnings will reveal whether the company can sustain growth in competitive pharma markets. With expected EPS of $0.925 and revenue of $10.99 billion, management typically beats earnings while missing revenue targets, prioritizing profitability. Meyka AI assigns a B+ grade based on solid fundamentals and reasonable 12.3x valuation. Investors should monitor GLP-1 product momentum and cash flow sustainability. At $44.35, the stock offers reasonable value for long-term healthcare investors seeking dividend income and obesity treatment exposure.
FAQs
What EPS and revenue are analysts expecting from Novo Nordisk?
Analysts expect $0.925 EPS and $10.99 billion revenue for the May 6 earnings report, representing a slight decline from recent quarters due to cautious market sentiment and seasonal pharmaceutical demand factors.
Has Novo Nordisk beaten earnings estimates recently?
Yes, Novo Nordisk beat EPS estimates in three of four recent quarters ($0.94–$0.961 actual versus $0.885–$0.935 estimates), but missed revenue in three of four reports, indicating strong cost control but ongoing revenue challenges.
What is Meyka AI’s rating for NONOF?
Meyka AI rates NONOF B+ based on S&P 500 comparison, sector performance, financial growth, and analyst consensus. This suggests balanced risk-reward and solid fundamentals for healthcare investors seeking dividend income and growth.
What should investors watch during this earnings report?
Monitor GLP-1 product sales, geographic revenue performance, gross margins, and cash flow trends. Watch management guidance on competitive pressures, pricing power, R&D investments, currency impacts, and biopharmaceutical segment performance.
Will Novo Nordisk beat or miss earnings estimates?
An EPS beat appears likely based on three consecutive beats. Revenue remains uncertain due to recent misses. Strong GLP-1 demand and cost discipline favor a beat, though competitive pressures pose downside risks.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)